{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"}],"units":"Participants"}],"description":"Percentage of participants who responded to the addition of tadalafil. Response is defined as a complete remission (CR), very good partial remission (VGPR), partial remission (PR), or stable disease (SD) by International Uniform Response criteria.","groups":[{"description":"Subject will take tadalafil in combination with with Lenalidomide and dexamethasone (Rd) or Clarithromycin/Lenalidomide/ dexamethasone (BiRd)\n\nTadalafil: Tadalafil will be administered at a dose of 20 mg orally daily starting with day 1 of the first cycle. Each cycle will last for 28 days\n\nLenalidomide: Lenalidomide will be administered as it was prior to study entry.\n\nDexamethasone: Dexamethasone will be administered as it was prior to study entry.\n\nClarithromycin: Clarithromycin will be administered as it was prior to study entry.","id":"OG000","title":"Tadalafil"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"One participant was not analyzed because he only received eight days of study drug prior to progression and removal from study. One participant was retrospectively ineligible and was therefore not analyzed.","reportingStatus":"POSTED","timeFrame":"Up to 6 months","title":"Response Rate","type":"PRIMARY","unitOfMeasure":"Participants"}